Investigational Drug Shows Potentialin Phase 3 Obesity Trial - Takeaways - MDSpire

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

  • By

  • Andrea Surnit

  • June 10, 2026

  • 4 min

Share

  • 1

    Survodutide significantly reduced body weight in patients with obesity over 76 weeks compared to placebo in the phase 3 SYNCHRONIZE-1 trial.

  • 2

    Patients receiving survodutide 3.6 mg and 6.0 mg achieved mean weight losses of approximately 12% and 13%, respectively, versus over 5% for placebo.

  • 3

    Higher percentages of patients on survodutide achieved substantial weight loss thresholds: 55% and 57% lost at least 10%, compared to 26% on placebo.

  • 4

    Survodutide also led to greater reductions in waist circumference and improvements in metabolic markers compared to placebo.

  • 5

    Adverse gastrointestinal events were more common in survodutide groups, with discontinuation rates due to these events at 18% and 20%.

Original Source(s)

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

  • by Andrea Surnit

  • June 10, 2026

Related Content

Multidisease Detection from Fundus Imaging

Researchers in China create AI framework aimed at using retinal imaging to screen for multiple systemic diseases

  • June 8, 2026

  • 3 min
Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial